Dr. Thoranis Chantrarat has informed the editor to correct the co-author’s lastname and text in the article “Heart Failure Council of Thailand (HFCT) 2019 Heart Failure Guideline: Sudden Cardiac Death and Device Therapy in Heart Failure” published in J Med Assoc Thai 2019, Vol.102, No.5, page 618-22 as follow:

1) from Kanjanavanich R to Kanjanavanit R

in page 618

2) from Patients with HF who develop sustained ventricular tachyarrhythmia (either sustained monomorphic or polymorphic VT, VF, or recurrent syncope with inducible sustained VT at the electrophysiological study) are candidates for ICD implantation, as long as they have a life expectancy of more than one year (Table 4).

to Patients with HF who develop sustained ventricular tachyarrhythmia (either sustained monomorphic or polymorphic VT, VF, or recurrent syncope with inducible sustained VT at the electrophysiological study) are candidates for ICD implantation, as long as they have a life expectancy of more than one year (Table 4). More than 10 PVCs per hour or runs of NSVT are acceptable markers of increased risk. If patients are symptomatic due to PVCs or NSVTs, or if PVCs or NSVTs contribute to reduced LVEF (tachycardia-induced cardiomyopathy), amiodarone or catheter ablation should be considered(9).

in page 619

3) from However, the same benefit was not observed in patients with non-LBBB conduction abnormalities (RR 0.97, 95% CI 0.82 to 1.15; p<0.75)(8). More than 10 PVCs per hour or runs of NSVT are acceptable markers of increased risk. If patients are symptomatic due to PVCs or NSVTs, or if PVCs or NSVTs contribute to reduced LVEF (tachycardia-induced cardiomyopathy), amiodarone or catheter ablation should be considered(9).

to However, the same benefit was not observed in patients with non-LBBB conduction abnormalities (RR 0.97, 95% CI 0.82 to 1.15; p<0.75)(8).

in page 620-621